Glenmark Pharmaceuticals Limited Share Price and Company Fundamentals



Price
₹389.35
Change
8.200 (2.151%)
52 week
348.5 - 690.95

Last traded: Yesterday at 9:59 AM

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Key Metrics

PE ratio

11.60

PB ratio

1.20

Dividend yield

0.66%

Beta

1.08

Market cap

-

Enterprise value

-

Company profile

Industry / SectorDrug Manufacturers—Specialty & Generic / Healthcare
Websitehttps://www.glenmarkpharma.com
Mailing addressGlenmark House B.D. Sawant Marg Chakala, Off Western Express Highway Andheri (East) Mumbai 400099 India
Phone / Fax91 22 4018 9999 / 91 22 4018 9986

Dividends

Dividend yield

0.66%

Dividend amount

₹2.50

Payout ratio

7.49%

5Y Avg. yield

0.46%

Glenmark Pharmaceuticals Limited paid ₹2.50 dividend and the ex-dividend date was 08 Sept 2021.The dividend payout ratio is 7.49%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.GLENMARK dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.

GLENMARK's forward dividend amount is ₹2.5 and the forward dividend yield is 0.66%. A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Jul 2022, following are the company executives and directors listed on Glenmark Pharmaceuticals Limited.

NameTitleAgeTotal Pay
Mr. Glenn Mario SaldanhaChairman, MD & CEO51138.57M
Mr. V. S. ManiGlobal CFO & Exec. Director5662.26M
Ms. Cherylann Maria PintoExec. Director of Corp. Services & Exec. Director5440.7M
Mr. Alind SharmaPres & Global Chief HR Officer50
Mr. Kaizad Adi HazariPres and Global Head of Legal, Compliance, IP & Corp. Affairs51
Dr. Darshan B. MakheyPres & Chief Quality Officer54
Mr. Sriram VenkatasubramanianPres & Head of Global Operations and Supply Chain
Dr. Nikhil AminPres of Innovative Medicines Group & Chief Scientific Officer
Mr. Ravi AgrawalInvestor Relations Officer
Udaykumar MurthySr. Mang. of Corp. Communications

Profitability and management effectiveness

Profit margin

7.55%

Operating margin

16.04%

Return on assets

7.65%

Return on equity

12.04%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Glenmark Pharmaceuticals Limited is and its enterprise value is .

The GLENMARK's stocks Beta value is 1.08 making it 8% more volatile compared to NSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Frequently Asked Questions

1. What is Glenmark Pharmaceuticals Limited's Stock Symbol?

Glenmark Pharmaceuticals Limited trades on NSE under the ticker symbol "GLENMARK".

2. What is Glenmark Pharmaceuticals Limited's stock price today?

One share of GLENMARK stock can currently be purchased for approximately ₹389.35.

3. How can I contact Glenmark Pharmaceuticals Limited?

Glenmark Pharmaceuticals Limited's mailing address is Glenmark House B.D. Sawant Marg Chakala, Off Western Express Highway Andheri (East) Mumbai 400099 India. The company can be reached via phone at 91 22 4018 9999.

4. What is Glenmark Pharmaceuticals Limited's official website?

The official website of Glenmark Pharmaceuticals Limited is https://www.glenmarkpharma.com.